| #52 |
Bernhard Helk |
Glykos Finland Oy |
1 |
| #52 |
Michael Lammbrigger |
Endress+Hauser Flowtec Ag |
1 |
| #52 |
Jose-Octavio Sorbara |
Dsm Ip Assets B.V. |
1 |
| #52 |
Carolina Haefliger |
Novartis Ag |
1 |
| #52 |
Benoit Hussherr |
Syngenta Participations Ag |
1 |
| #52 |
Masato MURAKAMI |
Novartis Ag |
1 |
| #52 |
Shinji Hatakeyama |
Novartis Ag |
1 |
| #52 |
Daniel Zimmermann |
Array Biopharma |
1 |
| #52 |
Ekaterina V. Breous-Nystrom |
Agenus |
1 |
| #52 |
Florian LIPSMEIER |
Hoffmann-La Roche |
1 |
| #52 |
Declan Reilly |
Hoffmann-La Roche |
1 |
| #52 |
Fionn O'Hara |
Hoffmann-La Roche |
1 |
| #52 |
Margit Jeschke |
Novartis Ag |
1 |
| #52 |
Gerhard Obrist |
Aerosol-Service Ag |
1 |
| #52 |
Marcel Jakob |
Universitatsspital Basel |
1 |
| #52 |
Martina Thier |
University of Michigan |
1 |
| #52 |
Thomas Tange Ostergaard |
Evolva Sa |
1 |
| #52 |
Eva Rödel |
Intrexon |
1 |
| #52 |
Horst Prescher |
— |
1 |
| #52 |
Massimo Pignone |
Novartis Ag |
1 |
| #52 |
Doris Stingelin |
Novartis Ag |
1 |
| #52 |
Lukas Giger |
Depuy Synthes Products |
1 |
| #52 |
Suzie Jesus Ribeiro |
Novartis Ag |
1 |
| #52 |
Franco E. Di Padova |
Novartis Ag |
1 |
| #52 |
Felix Bachmann |
Basilea Pharmaceutica Ag |
1 |
| #52 |
Lukas Hofstetter |
Abb Schweiz Ag |
1 |
| #52 |
Amjad Mallisho |
— |
1 |
| #52 |
Kai Urban |
Dsm Ip Assets B.V. |
1 |
| #52 |
Diana Graus Porta |
— |
1 |
| #52 |
Werner Heinz Pachinger |
Novartis Ag |
1 |
| #52 |
Heiner Bieli |
Straumann Holding Ag |
1 |
| #52 |
Jérôme Charles Sarie |
Hoffmann-La Roche |
1 |
| #52 |
Thomas Ullrich |
Novartis Ag |
1 |
| #52 |
Caroline KULANGARA |
— |
1 |
| #52 |
Rachel Kohli Steck |
— |
1 |
| #52 |
Karin RAPP |
Debiopharma S.A. |
1 |
| #52 |
Robert Jack Gillespie |
Hoffmann-La Roche |
1 |
| #52 |
Senthil Kumar RAMAN |
— |
1 |
| #52 |
Madlaina Breuleux |
Basilea Pharmaceutica Ag |
1 |
| #52 |
Roman Mathäs |
Hoffmann-La Roche |
1 |
| #52 |
Chikako Ogawa |
Eisai R&D Management Co. |
1 |
| #52 |
Jascha-Nikolai Rybak |
Philogen S.P.A. |
1 |
| #52 |
Christian Hirt |
Universitatsspital Basel |
1 |
| #52 |
Lars Schiefelbein |
Ferring B.V. |
1 |
| #52 |
Hans Jürg Kirner |
Basf Se |
1 |
| #52 |
Andreas Peer |
Genzyme |
1 |
| #52 |
Erik Jackson Bunn |
Basen |
1 |
| #52 |
Azagen Mootien |
Depuy Synthes Products |
1 |
| #52 |
Geraint Davies |
Hoffmann-La Roche |
1 |
| #52 |
Oliver Simic |
Novartis Ag |
1 |